FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer By Ogkologos - June 27, 2025 216 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ARANOTE study Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR Feasibility and Safety of Preoperative Treatment with Nivolumab and Relatlimab in... May 10, 2024 The American Society of Clinical Oncology and the American Cancer Society:... February 1, 2022 Happy Occupational Therapy Month April 19, 2023 Waiting for Insurance to Cover Her Mammogram Could Have Cost This... April 9, 2019 Load more HOT NEWS Sound Waves Can Target Lymph Nodes And Help Kill Breast Cancer... An Oncology Hospital at Home Model of Acute Care Shows Promise FOCUS4: Learning from a landmark clinical trial ESMO Targeted Anticancer Therapies Congress 2023
